Skip to content

Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06268561
Enrollment
8
Registered
2024-02-20
Start date
2023-06-05
Completion date
2024-06-30
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endophthalmitis

Keywords

OZURDEX, Visual Acuity, Endophtalmitis

Brief summary

OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.

Interventions

OTHERVisual acuity analysis

Collection of information on visual acuity from the medical file concerning the surgery

OTHERIntraocular pressure analysis

Collection of information on intraocular pressure from the medical file concerning the surgery

OTHERAnalysis of optical coherence tomography (OCT) images

Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery

OTHERAnalysis of retinograms

Collection and analysis of retinography images of the medical file concerning the surgery

Sponsors

Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patient who had endophtalmitis following an OZURDEX implant injection within 2 months

Exclusion criteria

* Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity2018 to 2023Evolution of visual acuity from the first to the last patient includes

Secondary

MeasureTime frameDescription
IOP measured in mmHg by tonometer and confirmed with Goldman Applanation2018 to 2023Changes intra ocular pressure.
Tomography2018 to 2023Changes in the outer retina on optical coherence tomography
Resumption of intravitreal therapy2018 to 2023Number of new intravitreal injections necessary to control the princeps pathology (AMD/OMD...) during the follow-up of the study ; i.e. relapse of activity of the princeps pathology

Countries

France

Contacts

Primary ContactThibaud GARCIN, MD PhD
thibaud.garcin@chu-st-etienne.fr(0)477829662
Backup ContactHenri PITEAU, resident
piteau.henri@gmail.com(0)477829662

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026